IL139479A0 - Heterocyclic compounds and pharmaceutical compositions containing the same - Google Patents
Heterocyclic compounds and pharmaceutical compositions containing the sameInfo
- Publication number
- IL139479A0 IL139479A0 IL13947999A IL13947999A IL139479A0 IL 139479 A0 IL139479 A0 IL 139479A0 IL 13947999 A IL13947999 A IL 13947999A IL 13947999 A IL13947999 A IL 13947999A IL 139479 A0 IL139479 A0 IL 139479A0
- Authority
- IL
- Israel
- Prior art keywords
- same
- pharmaceutical compositions
- compositions containing
- heterocyclic compounds
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Ceramic Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Structural Engineering (AREA)
- Obesity (AREA)
- Manufacturing & Machinery (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8505398P | 1998-05-11 | 1998-05-11 | |
US12762699P | 1999-04-01 | 1999-04-01 | |
US12909999P | 1999-04-13 | 1999-04-13 | |
PCT/US1999/010291 WO1999058502A1 (en) | 1998-05-11 | 1999-05-11 | Heterocyclic inhibitors of p38 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL139479A0 true IL139479A0 (en) | 2001-11-25 |
Family
ID=27375001
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13947999A IL139479A0 (en) | 1998-05-11 | 1999-05-11 | Heterocyclic compounds and pharmaceutical compositions containing the same |
IL139479A IL139479A (en) | 1998-05-11 | 2000-11-05 | Heterocyclic compounds and pharmaceutical preparations containing them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL139479A IL139479A (en) | 1998-05-11 | 2000-11-05 | Heterocyclic compounds and pharmaceutical preparations containing them |
Country Status (31)
Country | Link |
---|---|
US (4) | US6632945B2 (de) |
EP (3) | EP1077943B1 (de) |
JP (2) | JP4704560B2 (de) |
KR (1) | KR100696219B1 (de) |
CN (1) | CN1306512A (de) |
AP (1) | AP2000001996A0 (de) |
AT (1) | ATE417828T1 (de) |
AU (1) | AU764047B2 (de) |
BG (1) | BG65025B1 (de) |
BR (1) | BR9911786A (de) |
CA (1) | CA2331460C (de) |
CZ (1) | CZ300702B6 (de) |
DE (1) | DE69940115D1 (de) |
DK (1) | DK1077943T3 (de) |
EA (1) | EA200001176A1 (de) |
EE (1) | EE200000610A (de) |
ES (1) | ES2318893T3 (de) |
GE (1) | GEP20032954B (de) |
HK (1) | HK1034907A1 (de) |
HU (1) | HUP0105174A3 (de) |
IL (2) | IL139479A0 (de) |
IS (1) | IS5711A (de) |
MY (1) | MY132496A (de) |
NO (1) | NO319755B1 (de) |
NZ (1) | NZ508653A (de) |
PL (1) | PL198352B1 (de) |
PT (1) | PT1077943E (de) |
SK (1) | SK286689B6 (de) |
TW (1) | TWI249527B (de) |
UA (1) | UA74325C2 (de) |
WO (1) | WO1999058502A1 (de) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608060B1 (en) * | 1996-12-18 | 2003-08-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
JP2002504909A (ja) | 1997-06-13 | 2002-02-12 | スミスクライン・ビーチャム・コーポレイション | 新規な置換ピラゾールおよびピラゾリン化合物 |
DE69831085D1 (de) * | 1997-09-10 | 2005-09-08 | Dainippon Ink & Chemicals | 2,6-dichlor-4-pyridinmethanolderivate als chemikalien für die landwirtschaft |
WO2000040243A1 (en) | 1999-01-08 | 2000-07-13 | Smithkline Beecham Corporation | Novel compounds |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
BR0009721A (pt) | 1999-04-15 | 2002-02-13 | Bristol Myers Squibb Co | Inibidores de tirosina quinase de proteìna cìclica |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
AU5316900A (en) * | 1999-06-03 | 2000-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) |
AU1781601A (en) | 1999-11-23 | 2001-06-04 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
AU2001238651A1 (en) * | 2000-02-23 | 2001-09-03 | Iconix Pharmaceuticals, Inc. | Pyridine-amidines as modulators of p38 map kinase |
WO2001070695A1 (en) * | 2000-03-22 | 2001-09-27 | Vertex Pharmaceuticals Incorporated | Pyridine derivatives as inhibitors of p38 |
AU8323701A (en) * | 2000-08-11 | 2002-02-25 | John Cochran | Inhibitors of p38 |
US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
MXPA03010269A (es) | 2001-05-11 | 2004-05-05 | Vertex Pharma | Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38. |
EP1414455B1 (de) | 2001-06-11 | 2008-11-26 | Vertex Pharmaceuticals Incorporated | Isochinolin-inhibitoren von p38 |
US20030139435A1 (en) * | 2001-06-26 | 2003-07-24 | Gulzar Ahmed | N-heterocyclic inhibitors of TNF-alpha expression |
SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
ATE349210T1 (de) | 2002-07-09 | 2007-01-15 | Boehringer Ingelheim Pharma | Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |
CA2755297A1 (en) | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
PT1626714E (pt) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
AU2005233632A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
KR100575344B1 (ko) * | 2004-07-14 | 2006-05-03 | 주식회사 이큐스팜 | C형 간염 예방 및 치료용 약학적 조성물 |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
WO2006021848A1 (en) * | 2004-08-27 | 2006-03-02 | Ranbaxy Laboratories Limited | Anti-inflammatory agents |
US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
AU2006202209B2 (en) | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
BRPI0502016B8 (pt) * | 2005-06-03 | 2021-05-25 | Univ Federal Do Rio De Janeiro Ufrj | composto ureídicos, composições farmacêuticas contendo os mesmos e seu uso no tratamento de doenças inflamatórias |
JP2009500297A (ja) * | 2005-06-08 | 2009-01-08 | セントカー・インコーポレーテツド | 眼の変性についての細胞療法 |
US20070122448A1 (en) * | 2005-11-28 | 2007-05-31 | Alireza Rezania | Compositions and methods to create a vascularized environment for cellular transplantation |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
EP3527658B1 (de) | 2006-04-28 | 2024-07-24 | Janssen Biotech, Inc. | Differenzierung menschlicher embryonaler stammzellen |
WO2008094597A2 (en) * | 2007-01-30 | 2008-08-07 | University Of Georgia Research Foundation, Inc. | Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc) |
CA2681420A1 (en) * | 2007-03-20 | 2008-09-25 | Cadila Pharmaceuticals Limited | P38 inhibitors |
EP1992344A1 (de) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
ES2537578T3 (es) | 2007-07-18 | 2015-06-09 | Lifescan, Inc. | Diferenciación de las células madre de embriones humanos |
EP2610336A1 (de) | 2007-07-31 | 2013-07-03 | Lifescan, Inc. | Differenzierung von menschlichen embryonalen Stammzellen |
US9062290B2 (en) * | 2007-11-27 | 2015-06-23 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
CN105886459A (zh) | 2008-02-21 | 2016-08-24 | 詹森生物科技公司 | 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物 |
US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
KR20180018839A (ko) | 2008-06-30 | 2018-02-21 | 얀센 바이오테크 인코포레이티드 | 만능 줄기 세포의 분화 |
US20110305672A1 (en) | 2008-07-25 | 2011-12-15 | University Of Georgia Research Foundation, Inc. | COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME |
CN102165058B (zh) | 2008-07-25 | 2015-07-01 | 佐治亚大学研究基金会 | 中胚层来源的ISL 1+多潜能细胞(IMPs)的组合物、心外膜祖细胞(EPCs)和多潜能CXCR4+CD56+细胞(C56Cs)及其使用方法 |
US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
WO2010038428A1 (ja) * | 2008-09-30 | 2010-04-08 | 武田薬品工業株式会社 | タキサン系抗がん剤の置き換え薬 |
BRPI0919883A2 (pt) | 2008-10-31 | 2015-08-11 | Centocor Ortho Biotech Inc | Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática |
CA2742268C (en) | 2008-10-31 | 2020-02-18 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
CN102257132B (zh) * | 2008-11-20 | 2014-09-03 | 森托科尔奥索生物科技公司 | 用于在平面基底上进行细胞附着和培养的方法和组合物 |
AU2009316580B2 (en) | 2008-11-20 | 2016-04-14 | Janssen Biotech, Inc. | Pluripotent stem cell culture on micro-carriers |
JP2012511567A (ja) * | 2008-12-10 | 2012-05-24 | ドン ファ ファーム カンパニー リミテッド | 新規の2,6−置換−3−ニトロピリジン誘導体、その製造方法及びこれを含む薬学組成物 |
SG172160A1 (en) | 2008-12-17 | 2011-07-28 | Scripps Research Inst | Generation and maintenance of stem cells |
EP2396302A2 (de) * | 2009-02-13 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Verfahren zur herstellung von phenyl-6-(1-(phenyl)ureido)nicotinamiden |
GB0908317D0 (en) * | 2009-05-14 | 2009-06-24 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
CA2768643C (en) | 2009-07-20 | 2018-09-18 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
SG177416A1 (en) | 2009-07-20 | 2012-02-28 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
RU2540021C2 (ru) | 2009-07-20 | 2015-01-27 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека |
BR112012010136A2 (pt) | 2009-10-29 | 2015-09-15 | Janssen Biotech Inc | células -tronco pluripotentes |
ES2633648T3 (es) * | 2009-12-23 | 2017-09-22 | Janssen Biotech, Inc. | Diferenciación de células madre embrionarias humanas |
KR101867369B1 (ko) | 2009-12-23 | 2018-06-14 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
CN102791851B (zh) * | 2010-03-01 | 2017-07-14 | 詹森生物科技公司 | 纯化衍生自多能干细胞的细胞的方法 |
RU2587634C2 (ru) | 2010-05-12 | 2016-06-20 | Янссен Байотек, Инк. | Дифференцирование эмбриональных стволовых клеток человека |
SG187603A1 (en) | 2010-08-12 | 2013-03-28 | Janssen Biotech Inc | Treatment of diabetes with pancreatic endocrine precursor cells |
ES2658146T3 (es) | 2010-08-31 | 2018-03-08 | Janssen Biotech, Inc. | Diferenciación de células madre embrionarias humanas |
BR112013004614A2 (pt) | 2010-08-31 | 2024-01-16 | Janssen Biotech Inc | Diferenciação de células-tronco pluripotentes |
EP2611909B1 (de) | 2010-08-31 | 2018-01-17 | Janssen Biotech, Inc. | Differenzierung menschlicher embryonischer stammzellen |
WO2012073238A1 (en) | 2010-12-02 | 2012-06-07 | Technion Research & Development Foundation Ltd. | Methods of generating corneal cells and cell populations comprising same |
CA2816495C (en) | 2010-12-15 | 2020-10-13 | Kadimastem Ltd. | Insulin producing cells derived from pluripotent stem cells |
MX2014007744A (es) | 2011-12-22 | 2015-01-12 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionicas humanas en celulas individuales positivas de insulina hormonal. |
EP2823037A4 (de) | 2012-03-07 | 2015-09-16 | Janssen Biotech Inc | Definierte medien zur expansion und pflege pluripotenter stammzellen |
EP2843049B1 (de) | 2012-04-27 | 2018-04-11 | Keio University | Promoter für neuronale differenzierung |
PL2859091T3 (pl) | 2012-06-08 | 2019-01-31 | Janssen Biotech, Inc | Różnicowanie ludzkich zarodkowych komórek macierzystych w komórki endokrynne trzustki |
AU2013370228B2 (en) | 2012-12-31 | 2018-10-18 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
BR112015015701A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | diferenciação de células-tronco embrionárias humanas em células pancreáticas endócrinas com o uso de reguladores hb9 |
BR112015015770A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
JP6562897B2 (ja) | 2013-03-13 | 2019-08-21 | ユニバーシティー オブ マイアミUniversity Of Miami | 細胞培養上清および生体液からの微小胞の単離および精製のための方法 |
SG10201810739VA (en) | 2014-05-16 | 2019-01-30 | Janssen Biotech Inc | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
WO2017075274A1 (en) | 2015-10-27 | 2017-05-04 | Children's Hospital Medical Center | Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation |
IL293289B2 (en) | 2015-11-30 | 2024-04-01 | Kadimastem Ltd | Methods for differentiation and purification of pancreatic endocrine cells |
MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US11479770B2 (en) | 2017-10-05 | 2022-10-25 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of DUX4 |
KR20200121800A (ko) * | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
US10889548B2 (en) | 2018-03-26 | 2021-01-12 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
KR20230074475A (ko) | 2020-08-21 | 2023-05-30 | 더 유니버시티 오브 마이애미 | 골수-유래 중간엽 줄기 세포로부터의 미세소포를 사용한 치료의 조성물 및 방법 |
US20230390341A1 (en) | 2022-04-19 | 2023-12-07 | University Of Miami | Methods and compositions for prevention and treatment of graft versus host disease |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966622A (en) * | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
US4973690A (en) * | 1988-04-12 | 1990-11-27 | Ciba-Geigy Corporation | Novel ureas |
US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
JPH10512264A (ja) | 1995-01-12 | 1998-11-24 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
US6096748A (en) * | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6242569B1 (en) * | 1997-02-05 | 2001-06-05 | Tularik, Inc. | Regulators of apoptosis |
KR20010012808A (ko) * | 1997-05-22 | 2001-02-26 | 윌리암스 로저 에이 | p38 키나아제로서 4-아릴-3(5)-헤테로아릴 치환 피라졸 |
EP1414455B1 (de) * | 2001-06-11 | 2008-11-26 | Vertex Pharmaceuticals Incorporated | Isochinolin-inhibitoren von p38 |
-
1999
- 1999-05-10 MY MYPI99001841A patent/MY132496A/en unknown
- 1999-05-11 KR KR1020007012601A patent/KR100696219B1/ko not_active IP Right Cessation
- 1999-05-11 ES ES99920427T patent/ES2318893T3/es not_active Expired - Lifetime
- 1999-05-11 CZ CZ20004172A patent/CZ300702B6/cs not_active IP Right Cessation
- 1999-05-11 TW TW088107631A patent/TWI249527B/zh not_active IP Right Cessation
- 1999-05-11 EA EA200001176A patent/EA200001176A1/ru unknown
- 1999-05-11 CA CA2331460A patent/CA2331460C/en not_active Expired - Fee Related
- 1999-05-11 IL IL13947999A patent/IL139479A0/xx unknown
- 1999-05-11 EP EP99920427A patent/EP1077943B1/de not_active Expired - Lifetime
- 1999-05-11 PL PL344046A patent/PL198352B1/pl not_active IP Right Cessation
- 1999-05-11 AT AT99920427T patent/ATE417828T1/de active
- 1999-05-11 HU HU0105174A patent/HUP0105174A3/hu unknown
- 1999-05-11 AU AU37923/99A patent/AU764047B2/en not_active Ceased
- 1999-05-11 PT PT99920427T patent/PT1077943E/pt unknown
- 1999-05-11 NZ NZ508653A patent/NZ508653A/en not_active IP Right Cessation
- 1999-05-11 SK SK1688-2000A patent/SK286689B6/sk not_active IP Right Cessation
- 1999-05-11 DE DE69940115T patent/DE69940115D1/de not_active Expired - Lifetime
- 1999-05-11 WO PCT/US1999/010291 patent/WO1999058502A1/en not_active Application Discontinuation
- 1999-05-11 EE EEP200000610A patent/EE200000610A/xx unknown
- 1999-05-11 JP JP2000548306A patent/JP4704560B2/ja not_active Expired - Fee Related
- 1999-05-11 GE GEAP19995666A patent/GEP20032954B/en unknown
- 1999-05-11 EP EP10177856A patent/EP2336111A1/de not_active Withdrawn
- 1999-05-11 AP APAP/P/2000/001996A patent/AP2000001996A0/en unknown
- 1999-05-11 BR BR9911786-0A patent/BR9911786A/pt not_active Application Discontinuation
- 1999-05-11 DK DK99920427T patent/DK1077943T3/da active
- 1999-05-11 EP EP08021820A patent/EP2062879A1/de not_active Withdrawn
- 1999-05-11 CN CN99807647A patent/CN1306512A/zh active Pending
- 1999-05-11 UA UA2000127087A patent/UA74325C2/uk unknown
-
2000
- 2000-11-05 IL IL139479A patent/IL139479A/en not_active IP Right Cessation
- 2000-11-10 NO NO20005673A patent/NO319755B1/no not_active IP Right Cessation
- 2000-11-10 IS IS5711A patent/IS5711A/is unknown
- 2000-12-07 BG BG105031A patent/BG65025B1/bg unknown
- 2000-12-21 US US09/746,722 patent/US6632945B2/en not_active Expired - Fee Related
-
2001
- 2001-08-13 HK HK01105642.0A patent/HK1034907A1/xx not_active IP Right Cessation
-
2003
- 2003-08-08 US US10/638,126 patent/US7115637B2/en not_active Expired - Fee Related
-
2006
- 2006-05-08 US US11/430,512 patent/US7423049B2/en not_active Expired - Fee Related
-
2008
- 2008-08-01 US US12/184,996 patent/US20090075981A1/en not_active Abandoned
-
2010
- 2010-03-12 JP JP2010056785A patent/JP2010150282A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL139479A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
IL148517A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
IL150077A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
HUP0103256A3 (en) | Thiobenzimidazole derivatives and pharmaceutical compositions containing the compounds | |
IL138899A0 (en) | Amidene derivatives and pharmaceutical compositions containing the same | |
IL141456A0 (en) | Rhodanine derivatives and pharmaceutical compositions containing the same | |
IL138573A0 (en) | Amide derivatives and pharmaceutical compositions containing the same | |
IL144592A0 (en) | Heterocyclic aromatic compounds and pharmaceutical compositions containing the same | |
IL143920A0 (en) | 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same | |
HUP0203378A3 (en) | Pharmaceutical compounds and pharmaceutical compositions containing them | |
IL144977A0 (en) | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
IL135176A0 (en) | Benzothiazole derivatives and pharmaceutical compositions containing the same | |
IL144910A0 (en) | Cyclic compounds and pharmaceutical compositions containing the same | |
HUP0100949A3 (en) | Aryl fused azapolycyclic compounds and pharmaceutical compositions containing the same | |
IL142665A0 (en) | Acyl dipeptidyl derivatives and pharmaceutical compositions containing the same | |
IL145428A0 (en) | Alkanoyl-substituted heterocyclic derivatives and pharmaceutical compositions containing the same | |
IL110743A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
HUP0001154A3 (en) | 3-piperidyl-4-oxoquinazoline derivatives and medicincal compositions containing the same | |
IL143841A0 (en) | Amide compounds and pharmaceutical compositions containing the same | |
HUP0004398A3 (en) | Alpha-aryl-n-alkylnitrones and pharmaceutical compositions containing the same | |
IL136937A0 (en) | τ-GLUTAMYL AND β-ASPARTYL CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
IL138725A0 (en) | Sulfonamide derivatives and pharmaceutical compositions containing the same | |
HUP0101381A3 (en) | Benzofurylpyrone derivatives and pharmaceutical compositions containing them | |
IL149883A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
IL133097A0 (en) | Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof |